Lexaria Bioscience Meets Multi-Billion-Dollar Pharma, Highlights GLP-1 Safety Shift
LEXX•Lexaria Bioscience Corp held meetings with companies ranging from tech-focused startups to multi-billion-dollar pharmaceutical firms at the 2026 BIO International Convention to explore new and existing partnership opportunities. The company noted a sector-wide shift toward GLP-1 drug safety and tolerability and reported renewed interest in its DehydraTECH delivery for CBD and nicotine applications.
1. Positive Meetings at BIO Convention
Lexaria secured a full schedule of meetings at the 2026 BIO International Convention in San Diego, engaging with a spectrum of potential partners from innovative smaller tech firms to established multi-billion-dollar pharmaceutical companies to discuss exploratory and ongoing collaborations.
2. GLP-1 Sector Shift to Safety and Tolerability
Attendees highlighted a growing industry focus on balancing weight-loss efficacy with improved tolerability and safety profiles in GLP-1 therapies, a trend that aligns with Lexaria's DehydraTECH platform designed to enhance bio-absorption while minimizing adverse events.
3. Renewed Interest in CBD and Nicotine Applications
Beyond its GLP-1 engagements, Lexaria reported a resurgence of corporate interest in its DehydraTECH-CBD and DehydraTECH-nicotine programs, building on extensive prior R&D demonstrating the technology’s capacity to increase absorption and reduce side effects.
